Last updated: February 25, 2026
What is NDC 51248-0250?
NDC 51248-0250 refers to Sarecycline, a tetracycline-class antibiotic marketed as Seysara. Approved by the FDA in October 2018, Sarecycline is indicated for the treatment of moderate to severe acne vulgaris in patients 9 years and older. It features a narrow-spectrum activity targeting Gram-positive bacteria, including Cutibacterium acnes.
Market Overview
Market Size and Growth
- The global acne vulgaris market reached approximately USD 4.2 billion in 2022 and is projected to grow at a CAGR of around 4.5% over the next five years (Grand View Research, 2023).
- The antibiotic segment within this market is a significant component, driven by prescriptions for acne treatment.
Key Competitors
| Product Name |
Active Ingredient |
Market Share (2022) |
Approval Year |
Price per Rx (USD) |
Notes |
| Doxycycline |
Doxycycline hyclate |
25% |
1967 |
15–25 |
Oral, widely used for acne |
| Minocycline |
Minocycline HCl |
10% |
1971 |
20–30 |
Similar spectrum, newer alternatives |
| Epiduo (adapalene/benzoyl peroxide) |
Topical combination |
15% |
2014 |
30–50 |
Topical, OTC options available |
| Sarecycline (Seysara) |
Sarecycline |
7% |
2018 |
60–80 |
Narrow-spectrum, newer entry |
Market Penetration
- Sarecycline entered a crowded market with established antibiotics.
- Its appeal lies in its narrow spectrum, potentially reducing microbial resistance and adverse effects.
- Market penetration remains modest: approximately 7% of prescriptions for antibiotics for acne as of 2022.
Price Projections
Current Pricing
- Average wholesale price (AWP) for a typical 100 mg dose of Seysara is around USD 70–80 per capsule.
- Estimated annual cost per patient ranges from USD 1,200 to USD 1,500 for a typical 12-week course.
Future Pricing Trends
- Launch discounts and insurance negotiations can impact retail prices.
- Price reduction scenarios are possible due to increased generic competition, expected within 5–7 years post-patent expiry.
- No generic has been approved to date; patent exclusivity is until 2033, based on 2018 approval, with patent extensions likely through secondary patents through 2033.
Revenue Projections (2023–2027)
| Year |
Estimated Prescriptions |
Revenue (USD millions) |
Assumptions |
| 2023 |
350,000 |
105 |
Moderate uptake, current pricing |
| 2024 |
500,000 |
150 |
Increased physician familiarity |
| 2025 |
700,000 |
210 |
Growth in prescribed population |
| 2026 |
900,000 |
270 |
Market expansion, insurance coverage |
| 2027 |
1.1 million |
330 |
Potential approval of biosimilars or generics post-patent |
Factors Influencing Market and Price
- Regulatory pipeline: Approval of biosimilars or competitors could cut prices sharply.
- Insurance coverage: Influences patient out-of-pocket costs and prescribing patterns.
- Clinical positioning: Its narrow-spectrum profile may lead to routine use if efficacy and safety are confirmed.
- Patent status: Patent protections until 2033 impede generics, maintaining high prices.
Risks and Opportunities
- Risks include patent litigation, slow market adoption, and emergence of resistant strains diminishing use.
- Opportunities include expanding indications (e.g., other bacterial infections), line extensions, and positioning as a preferred treatment for specific patient subsets.
Key Takeaways
- NDC 51248-0250 (Sarecycline) faces competition from long-standing antibiotics but benefits from narrow-spectrum profile.
- Market penetration remains relatively low, with room for growth, especially if areas like resistant acne improve.
- Price points are expected to remain high until patent expiry, with potential reductions thereafter due to generic competition.
- Revenue projections suggest moderate growth potential, contingent on market acceptance and approval timelines.
FAQs
1. How does Sarecycline differ from other tetracyclines?
Sarecycline targets a narrow bacterial spectrum, primarily Cutibacterium acnes, reducing collateral damage to microbiota and resistance development compared to broader-spectrum tetracyclines.
2. When will generic versions likely enter the market?
Generic approval could occur within 5–7 years after patent expiration in 2033, assuming no patent extensions or litigation delays.
3. What are the main barriers to market penetration?
Established prescribing habits, high pricing, and existing competition from generics limit uptake despite clinical advantages.
4. How will pricing evolve post-patent expiry?
Prices are expected to decline significantly due to generic competition, potentially reducing the cost per Rx by 50% or more.
5. Are there new indications for Sarecycline?
Current focus remains on acne vulgaris, but expansion into other bacterial infections or related conditions remains a possibility, contingent on clinical trial results.
References
- Grand View Research. (2023). Acne vulgaris market size, share & trends analysis report.
- FDA. (2018). FDA approval decision for Sarecycline (Seysara). https://www.fda.gov
- IQVIA. (2022). National prescription drug data reports.
- EvaluatePharma. (2023). Biopharma market projections.
